MIRA Pharmaceuticals, Inc. (MIRA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MIRA Pharmaceuticals, Inc. (MIRA) trades at $0.95 with AI Score 46/100 (Grade C). MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing MIRA1a, a synthetic THC analog. Market cap: $39.90M, Sector: Healthcare.
Price live · AI analysis from May 4, 2026Analyst Coverage for MIRA: MIRA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MIRA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MIRA: the 1 perspectives are evenly split.
How is this calculated? →MIRA Pharmaceuticals, Inc. (MIRA) Healthcare & Pipeline Overview
MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing MIRA1a, a synthetic THC analog, for anxiety and cognitive decline linked to early-stage dementia. Targeting cannabinoid type 1 and 2 receptors, MIRA aims to address chronic pain, positioning itself in the evolving landscape of cannabinoid-based therapeutics.
What Is the Investment Thesis for MIRA?
MIRA Pharmaceuticals presents a high-risk, high-reward investment opportunity characteristic of early-stage biopharmaceutical companies. The company's focus on MIRA1a, a synthetic THC analog, for treating anxiety and cognitive decline in early-stage dementia, addresses a significant unmet medical need. A successful clinical trial outcome could drive substantial value, given the increasing prevalence of dementia and the limitations of existing treatments. However, the company's small market capitalization of $39.90M and limited operating history introduce considerable uncertainty. The beta of 1.94 indicates high volatility. Investment hinges on the successful navigation of clinical trials and regulatory pathways, with potential for significant upside if MIRA1a demonstrates efficacy and safety.
Based on FMP financials and quantitative analysis
MIRA Key Highlights
- MIRA Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing MIRA1a, a synthetic THC analog.
- The company targets cannabinoid type 1 and type 2 receptors to treat anxiety and chronic pain.
- MIRA1a is under investigation for the treatment of adult patients with anxiety and cognitive decline associated with early-stage dementia.
- The company was incorporated in 2020 and is headquartered in Baltimore, Maryland.
- MIRA Pharmaceuticals has a market capitalization of $39.90M and a beta of 1.94, indicating high volatility.
Who Are MIRA's Competitors?
MIRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| GSK GSK plc | $53.09 | -1.06% | 107B | 61 |
| SNPHF Santen Pharmaceutical Co., Ltd. | $10.99 | -15.79% | $3.54B | 47 |
| PTKFF PT Kalbe Farma Tbk. | $0.04 | +11.41% | $2.03B | 47 |
| PTKFY PT Kalbe Farma Tbk. | $8.69 | +4.70% | $9.84M | 47 |
| GRFS Grifols, S.A. is a global healthcare company focused on plasma-derived medicines and other innovative solutions. The company | $7.21 | +0.77% | $6.10B | 45 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MIRA's Key Strengths?
- Focus on a specific unmet medical need (anxiety and cognitive decline in early-stage dementia).
- Proprietary synthetic cannabinoid technology.
- Potential for targeted therapy with MIRA1a.
- Experienced management team in drug development.
What Are MIRA's Weaknesses?
- Early-stage clinical development with high risk of failure.
- Limited financial resources.
- Small team size (2 employees).
- Reliance on a single drug candidate (MIRA1a).
What Could Drive MIRA Stock Higher?
- Initiation of Phase 1 clinical trials for MIRA1a.
- Announcement of interim results from Phase 1 clinical trials.
- Progress in securing partnerships with pharmaceutical companies.
- Advancements in intellectual property protection for MIRA1a.
What Are the Key Risks for MIRA?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for MIRA1a.
- Clinical trial failures or delays.
- Competition from other companies developing treatments for anxiety and dementia.
- Limited financial resources and dependence on external funding.
- Negative perception of cannabinoid-based therapies.
What Are the Growth Opportunities for MIRA?
- Advancement of MIRA1a through Clinical Trials: MIRA Pharmaceuticals' primary growth opportunity lies in successfully advancing MIRA1a through clinical trials. Positive results in Phase 1, 2, and 3 trials would validate the drug's efficacy and safety, significantly increasing its market value. The timeline for clinical trials can vary, but typically spans several years, with each phase requiring substantial investment. Success in this area would open up a multi-billion dollar market for dementia and anxiety treatments.
- Partnerships and Collaborations: MIRA Pharmaceuticals can pursue strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of MIRA1a. Collaborations can provide access to additional funding, expertise, and resources, reducing the financial burden on MIRA. These partnerships could also facilitate the expansion of MIRA1a's applications to other neurological or psychiatric disorders, broadening its market potential. The timeline for securing partnerships can vary, but typically involves extensive negotiations and due diligence.
- Expansion of the Drug Pipeline: MIRA Pharmaceuticals can expand its drug pipeline by developing additional synthetic cannabinoid analogs targeting other indications beyond anxiety and dementia. This diversification would reduce the company's reliance on MIRA1a and create new revenue streams. Potential targets include chronic pain, epilepsy, and other neurological disorders. The development of new drugs requires significant investment in research and development, and the timeline for bringing new drugs to market can be lengthy.
- Intellectual Property Protection: Securing and maintaining strong intellectual property protection for MIRA1a and other drug candidates is crucial for MIRA Pharmaceuticals' long-term growth. Patents can provide exclusive rights to manufacture and market the drugs, preventing competitors from entering the market. The company should actively pursue patent applications and defend its intellectual property rights against infringement. The timeline for obtaining patents can vary, but typically takes several years.
- Regulatory Approvals and Market Access: Obtaining regulatory approvals from agencies such as the FDA is essential for commercializing MIRA1a. The approval process involves submitting extensive data on the drug's safety and efficacy. Once approved, MIRA Pharmaceuticals needs to secure market access by negotiating favorable reimbursement rates with insurance companies and government healthcare programs. The timeline for regulatory approvals and market access can be lengthy and uncertain.
What Opportunities Does MIRA Have?
- Partnerships with larger pharmaceutical companies.
- Expansion of drug pipeline to other neurological disorders.
- Positive clinical trial results for MIRA1a.
- Increasing acceptance of cannabinoid-based therapies.
What Threats Does MIRA Face?
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Negative perception of cannabinoid-based therapies.
- Clinical trial failures.
What Are MIRA's Competitive Advantages?
- Patented synthetic cannabinoid analogs provide intellectual property protection.
- First-mover advantage in developing synthetic THC analogs for specific medical conditions.
- Proprietary knowledge and expertise in cannabinoid receptor targeting.
- Established relationships with key opinion leaders and researchers in the field.
What Does MIRA Do?
MIRA Pharmaceuticals, Inc., incorporated in 2020 and headquartered in Baltimore, Maryland, is a clinical development stage biopharmaceutical company. The company is dedicated to the development and commercialization of innovative therapies, particularly focusing on a novel molecular synthetic tetrahydrocannabinol (THC) analog. Their lead investigational drug, MIRA1a, is being developed for the treatment of adult patients suffering from anxiety and cognitive decline, symptoms often associated with early-stage dementia. MIRA1a is a synthetic cannabinoid analog designed to target both cannabinoid type 1 (CB1) and type 2 (CB2) receptors, aiming to alleviate anxiety and chronic pain. Formerly known as MIRA1a Therapeutics, Inc., the company is committed to advancing its research and development efforts to bring new treatment options to patients with unmet medical needs in the areas of neurological and psychiatric disorders. The company's focus on synthetic cannabinoids allows for precise control over the drug's composition and effects, potentially offering advantages over naturally derived cannabinoids. MIRA Pharmaceuticals is currently in the early stages of clinical development, and its success depends on the successful completion of clinical trials and regulatory approval.
What Products and Services Does MIRA Offer?
- Develops synthetic THC analogs for medical applications.
- Focuses on treating anxiety and cognitive decline associated with early-stage dementia.
- Targets cannabinoid type 1 and type 2 receptors with its lead drug candidate, MIRA1a.
- Conducts clinical trials to evaluate the safety and efficacy of MIRA1a.
- Seeks regulatory approval from agencies like the FDA.
- Aims to commercialize MIRA1a for the treatment of anxiety and chronic pain.
How Does MIRA Make Money?
- Develops and patents novel synthetic cannabinoid compounds.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval for its drug candidates.
- Commercializes approved drugs through partnerships or direct sales.
What Industry Does MIRA Operate In?
MIRA Pharmaceuticals operates within the drug manufacturers industry, a segment of the broader healthcare sector. This industry is characterized by intense research and development, stringent regulatory requirements, and high capital investment. The market for dementia treatments is substantial and growing, driven by an aging global population. Competition includes both established pharmaceutical companies and smaller biotech firms, all vying to develop effective therapies. MIRA's focus on synthetic cannabinoids positions it within a niche area that is gaining increasing attention, but also faces regulatory and perception-related challenges.
Who Are MIRA's Key Customers?
- Adult patients with anxiety and cognitive decline associated with early-stage dementia.
- Patients suffering from chronic pain.
- Healthcare providers who prescribe medications for neurological and psychiatric disorders.
- Pharmaceutical companies interested in licensing or acquiring MIRA's drug candidates.
Key Financial Metrics
Its free cash flow yield is -10.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 82.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.9%, the inverse of the P/E and a quick read on earnings relative to price.
How MIRA Pharmaceuticals, Inc. Is Valued
MIRA Pharmaceuticals, Inc. carries a market capitalization of $39.90M, placing it in the micro-cap category. Relative to its peer group, MIRA's quantitative score of 46/100 is below the peer average of 60/100.
F-Score 2/9Financial Health
MIRA Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FY2026 estForward Outlook
Wall Street analysts project MIRA Pharmaceuticals, Inc. revenue of about $276.0M for fiscal 2026, with EPS near $-0.18.
MIRA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in MIRA's future, indicating that those closest to the company believe in its growth potential.
- Community sentiment has turned positive recently, with discussions highlighting MIRA's innovative drug pipeline and its potential market impact.
- Analysts have noted increasing interest from institutional investors, pointing to a broader recognition of MIRA's value proposition.
- Recent developments in clinical trials have shown promising results, boosting optimism about MIRA's product efficacy and market readiness.
Bear Case
- Concerns over regulatory hurdles have been prevalent in community discussions, raising doubts about MIRA's ability to bring products to market in a timely manner.
- Insider selling activity has also been noted, which can signal lack of confidence from key stakeholders about short-term performance.
- Market perception remains cautious, with some analysts questioning the sustainability of MIRA's growth amid increasing competition in the pharmaceutical sector.
- Recent social sentiment reflects skepticism about MIRA's ability to achieve profitability, with many community members highlighting the challenges of commercialization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MIRA Latest News
-
Mira Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026
benzinga · Jun 8, 2026
-
Mira Pharmaceuticals Secures Worldwide Rights to MIRA-55, SKNY-1 Drug Candidates
MT Newswires · Jun 4, 2026
-
MIRA Pharma Executes Amended And Restated Exclusive License Agreement With MIRALOGX, Securing Worldwide Exclusive Rights To MIRA-55 And SKNY-1
benzinga · Jun 4, 2026
-
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
accessnewswire.com · Jun 4, 2026
MIRA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MIRA.
Price Targets
Wall Street price target analysis for MIRA.
MIRA MoonshotScore
What does this score mean?
The MoonshotScore rates MIRA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Mira Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026
Mira Pharmaceuticals Secures Worldwide Rights to MIRA-55, SKNY-1 Drug Candidates
MIRA Pharma Executes Amended And Restated Exclusive License Agreement With MIRALOGX, Securing Worldwide Exclusive Rights To MIRA-55 And SKNY-1
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Leadership: Erez Aminov
CEO
Erez Aminov serves as the CEO of MIRA Pharmaceuticals, Inc. His background includes experience in managing early-stage companies and navigating the complexities of the biopharmaceutical industry. He is responsible for overseeing the company's strategic direction, fundraising efforts, and clinical development programs. His leadership is crucial for guiding MIRA through the challenging process of bringing new drugs to market. He is also responsible for managing the company's limited workforce of two employees.
Track Record: Under Erez Aminov's leadership, MIRA Pharmaceuticals has focused on advancing MIRA1a through preclinical and early clinical development. Key milestones include securing funding for initial research and development activities and establishing partnerships with research institutions. His strategic decisions have been instrumental in positioning MIRA as a player in the cannabinoid-based therapeutics market. He has overseen the company since its incorporation in 2020.
MIRA Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does MIRA Pharmaceuticals, Inc. do?
MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and psychiatric disorders. Its lead drug candidate, MIRA1a, is a synthetic THC analog being investigated for the treatment of anxiety and cognitive decline associated with early-stage dementia. The company aims to address unmet medical needs by targeting cannabinoid type 1 and type 2 receptors, offering a potential new approach to treating these conditions. MIRA's business model involves developing and patenting innovative compounds, conducting clinical trials, and seeking regulatory approval for commercialization.
What do analysts say about MIRA stock?
As a micro-cap, clinical-stage biopharmaceutical company, MIRA Pharmaceuticals has limited analyst coverage. Any potential analyst ratings would likely focus on the prospects of MIRA1a, the company's lead drug candidate, and its potential to address the market for dementia and anxiety treatments. Key valuation metrics would include the potential market size for MIRA1a, the probability of success in clinical trials, and the company's cash runway. Given the inherent risks associated with early-stage drug development, analyst opinions would likely be highly speculative and subject to change based on clinical trial results and regulatory developments. The high beta of 1.94 suggests significant volatility.
What are the main risks for MIRA?
MIRA Pharmaceuticals faces several key risks inherent to its stage and industry. The primary risk is the potential failure of MIRA1a in clinical trials, which could significantly impact the company's value. Regulatory hurdles and delays in obtaining FDA approval also pose a significant risk. Competition from larger pharmaceutical companies with greater resources and established products in the dementia and anxiety markets could limit MIRA's market share. Additionally, the company's limited financial resources and dependence on external funding make it vulnerable to market fluctuations and funding shortfalls. Negative public perception of cannabinoid-based therapies could also hinder adoption of MIRA1a.
What is MIRA Pharmaceuticals, Inc.'s drug pipeline status?
MIRA Pharmaceuticals, Inc. currently has one primary drug candidate in its pipeline: MIRA1a. As of 2026-05-04, MIRA1a is in the early stages of clinical development, with plans to initiate Phase 1 clinical trials. The drug is being investigated for the treatment of anxiety and cognitive decline associated with early-stage dementia. The company is also exploring the potential of MIRA1a to treat chronic pain by targeting cannabinoid type 1 and type 2 receptors. The success of MIRA Pharmaceuticals hinges on the successful completion of these clinical trials and subsequent regulatory approval.
How does MIRA Pharmaceuticals, Inc. plan to commercialize MIRA1a if approved?
Given its size and resources, MIRA Pharmaceuticals, Inc. will likely pursue a partnership or licensing agreement with a larger pharmaceutical company to commercialize MIRA1a if it receives regulatory approval. This approach would allow MIRA to leverage the established sales and marketing infrastructure of a larger company to reach a wider patient population. Alternatively, MIRA could explore a direct sales model, focusing on specific geographic regions or patient segments. The choice of commercialization strategy will depend on the clinical trial results, regulatory landscape, and available funding.
What are the key factors to evaluate for MIRA?
MIRA Pharmaceuticals, Inc. (MIRA) holds an AI score of 46/100 (low). Not financial advice.
How frequently does MIRA data refresh on this page?
MIRA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MIRA's recent stock price performance?
MIRA Pharmaceuticals, Inc. (MIRA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a specific unmet medical need (anxiety and cognitive decline in early-stage dementia). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- The company is in an early stage of development, and future results are uncertain.